Logo

Ambit to Profile Additional Compounds for Bristol-Myers, GSK, Pfizer

Jan 17, 2005

NEW YORK, Jan. 17 (GenomeWeb News) - Ambit Biosciences will profile additional compounds for Bristol-Myers Squibb, GlaxoSmithKline, and Pfizer using its kinase and screening technologies, the San Diego-based company said today.

 

Ambit will use its kinase platform to profile the specificity of certain compounds from GSK and Bristol-Myers. The platform consists of more than 170 quantitative, high-throughput kinase assays.

 

The company will also try to identify and characterize the protein targets of certain Pfizer compounds using its reverse screening technology that covers a large fraction of all human proteins.

 

Ambit has had previous collaborations with all three drug makers.

Breaking News
The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.